Epithelica develops local, one‑time genetic treatments for severe inherited skin diseases. The first program targets Autosomal Recessive Congenital Ichthyosis (ARCI), a rare, disfiguring disease with only symptomatic care today. The treatment is applied to the skin, aims to correct the disease‑causing change in the patient’s own stem cells, and is designed to cut daily care time, complications, and long‑term costs. The same approach can be extended to other genetic skin diseases such as Epidermolysis Bullosa, creating a focused but expandable pipeline.

Epithelica holds key patents and orphan drug designation from FDA and EMA for ARCI and uses JPM/BIO Partnering to secure funding and strategic partners to bring this therapy into the clinic.